Premium
Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum ( EDF ) in cooperation with the European Academy of Dermatology and Venereology ( EADV )
Author(s) -
Hertl M.,
Jedlickova H.,
Karpati S.,
Marinovic B.,
Uzun S.,
Yayli S.,
Mimouni D.,
Borradori L.,
Feliciani C.,
Ioannides D.,
Joly P.,
Kowalewski C.,
Zambruno G.,
Zillikens D.,
Jonkman M.F.
Publication year - 2015
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.12772
Subject(s) - venereology , medicine , pemphigus , guideline , dermatology , european union , paraneoplastic pemphigus , pathology , immunology , antibody , business , economic policy , autoantibody
Background Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available. Objectives For this reason, a group of European dermatologists with a long‐standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus. Results This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum ( EDF ) for a final consensus with the European Academy of Dermatology and Venereology ( EADV ) and the European Union of Medical Specialists ( UEMS ).